Literature DB >> 15966512

A non-functioning pituitary adenoma initially mimicking a microprolactinoma: The case for long-term follow-up of patients with mild hyperprolactinemia?

M Losa1, P Mortini, M Giovanelli.   

Abstract

OBJECTIVE: A correct differential diagnosis of patients with mild hyperprolactinemia is essential to select the most appropriate treatment modality. CLINICAL
PRESENTATION: A 50-yr-old woman presented to our Department for evaluation of an intra- and suprasellar mass causing progressive visual defect. Mild hyperprolactinemia causing menstrual irregularities was diagnosed in February 1989. In 1992, serum PRL levels ranged from 50 to 70 microg/l and magnetic resonance imaging (MRI) of the hypothalamic-pituitary region showed the presence of a 7 mm microadenoma. Bromocriptine therapy resulted in normalization of PRL levels and menstrual cycle, while a repeat MRI showed no change. Menses stopped in March 1998, when the patient was 46 yr old. Subsequently, the patient complained of worsening headaches and, starting from July 2001, visual disturbances. In March 2002, MRI showed a large pituitary tumor, measuring 40x37x28 mm. In May 2002, the patient was operated through the transsphenoidal approach with apparent total tumor removal. Histological examination confirmed a pituitary adenoma that stained negative for all pituitary hormones. Four months after surgery, the patient reported an improvement of visual function. MRI of the hypothalamic-pituitary region, performed 4, 13 and 25 months after surgery, showed a partially empty sella with no evidence of residual tumor.
CONCLUSIONS: This case suggests that, to exclude the alternative diagnosis of nonfunctioning pituitary adenoma or another mass lesion of the hypothalamic-pituitary region, repeat neuroimaging studies during long-term follow-up may be advisable in patients with presumed microprolactinoma who did not show reduction of the tumor during dopaminergic therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15966512     DOI: 10.1007/bf03347205

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

1.  Cabergoline in the long-term therapy of hyperprolactinemic disorders.

Authors:  C Ferrari; A Paracchi; A M Mattei; S de Vincentiis; A D'Alberton; P Crosignani
Journal:  Acta Endocrinol (Copenh)       Date:  1992-06

Review 2.  Medical treatment of prolactinomas.

Authors:  M E Molitch
Journal:  Endocrinol Metab Clin North Am       Date:  1999-03       Impact factor: 4.741

Review 3.  Clinical review 110: Diagnosis and treatment of pituitary tumors.

Authors:  P U Freda; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

Review 4.  Endocrine inactive and gonadotroph adenomas: diagnosis and management.

Authors:  M Losa; P Mortini; R Barzaghi; A Franzin; M Giovanelli
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

5.  Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.

Authors:  A Colao; D Ferone; S Lastoria; G Cerbone; A Di Sarno; C Di Somma; R Lucci; G Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2000-04       Impact factor: 3.478

6.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

7.  Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.

Authors:  Marco Losa; Pietro Mortini; Raffaella Barzaghi; Lorenzo Gioia; Massimo Giovanelli
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report.

Authors:  F C Albuquerque; D R Hinton; M H Weiss
Journal:  J Neurosurg       Date:  1998-12       Impact factor: 5.115

9.  Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.

Authors:  M V Smith; E R Laws
Journal:  Neurosurgery       Date:  1994-05       Impact factor: 4.654

10.  Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.

Authors:  D J Kwekkeboom; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-02       Impact factor: 3.478

View more
  1 in total

1.  Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels.

Authors:  Alina Livshits; Jelena Kravarusic; Ellie Chuang; Mark E Molitch
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.